This study explored the physiological and molecular mechanisms of yield increase in maize under stable soil water content (SW) conditions. Results of the study showed that under SW conditions, corn yield increased by 38.72 and 44.09% in 2019 and 2020, respectively. Further, it was found that dry matter accumulation, economic coefficient and photosynthetic rate also increased by 31.24 and 25.67%, 5.45 and 15.38% as well as 29.60 and 31.83% in 2019 and 2020 respectively. However, the results showed that both the activity of antioxidant enzymes and content of osmotic adjustment substances decreased in maize under SW conditions. When compared with soil moisture content of dry and wet alternation (DW) conditions, SW could not only significantly promote growth and yield of maize but also increase the economic coefficient. Transcriptome profiles of maize leaves under the two conditions (SW and DW) were also analyzed and compared. It was found that 11 genes were highly up-regulated in the photosynthesis pathway. These genes included photosystem II protein V (PsbE), photosystem II protein VI (PsbF), photosystem II protein D1 (PsbA), photosystem II protein D2 (PsbD) and ATP synthase CF1 beta subunit (atpB). Further, it was found that four genes were up-regulated in the oxidative phosphorylation pathway., These were ATP synthase CF1 epsilon subunit (atpE), ATP synthase CF1 beta subunit (atpB), NADH dehydrogenase subunit 4L (ndhE) and NADH dehydrogenase subunit 6 (ndhG). In conclusion, the physiological mechanism of stable soil water content (SW) to increase corn yield may be the enhancement of photosynthetic capacity and energy metabolism.

IntroductionThe aim of this study was to investigate the efficacy and safety of linagliptin + low-dose (LD) metformin once daily versus high-dose (HD) metformin twice daily in treatment-naïve patients with type 2 diabetes.MethodsPatients (n = 689) were randomized (1:1) to double-blind treatment with linagliptin 5 mg + LD metformin (1000 mg) or HD metformin (2000 mg) for 14 weeks. Metformin was initiated at 500 mg/day and up-titrated within 2 weeks; the dose then remained unchanged. The primary endpoint was change in glycated hemoglobin (HbA1c) from baseline to Week 14 in patients who tolerated a daily metformin dose of ≥1000 mg after 2 weeks.ResultsAt Week 14, HbA1c changed from a mean baseline of 8.0% (64 mmol/mol) by −0.99% (−11 mmol/mol) for linagliptin + LD metformin, and −0.98% (−11 mmol/mol) for HD metformin [treatment difference −0.01% (95% confidence interval −0.13, 0.12) (0 mmol/mol), P = 0.8924]. The proportion of patients who achieved HbA1c <7.0% (53 mmol/mol) without occurrence of moderate or severe gastrointestinal (GI) events (including abdominal pain, nausea, vomiting, diarrhea, and decreased appetite) was the same in both groups (51.3% for both). Although the occurrence of moderate or severe GI events was similar, the linagliptin + LD metformin group had fewer mild GI events (18.5% versus 24.3%). The incidence of hypoglycemia was low in both groups.ConclusionLinagliptin + LD metformin combination showed similar efficacy and safety to HD metformin. This combination may be an alternative treatment option in patients who may have difficulty tolerating metformin doses >1000 mg/day.FundingBoehringer Ingelheim.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-015-0195-3) contains supplementary material, which is available to authorized users.

Objective. To assess the efficacy of apatinib plus S-1 therapy in the treatment of advanced gastric cancer patients and the effect on the levels of tumor markers and Th1 and Th2-like cytokines. Methods. From October 2019 to December 2020, 100 patients with advanced gastric cancer assessed for eligibility were recruited and assigned at a ratio of 1 : 1 to receive either S-1 regimen (tegafur, gimeracil, and oteracil potassium capsules) (observation group) or apatinib plus S-1 therapy (experimental group). Outcome measures included clinical efficacy serum tumor marker levels, Th1 and Th2-like cytokine levels, time to progression (TTP), overall survival (OS), and adverse events. Results. The S-1 therapy plus apatinib was associated with a significantly higher efficacy versus S-1 therapy alone ( P  < 0.05). The eligible patients given S-1 therapy plus apatinib showed significantly lower levels of serum carcinoembryonic antigen (CEA), glycoantigen 199 (CA199), and glycoantigen 125 (CA125) versus those receiving S-1 therapy ( P  < 0.05). S-1 therapy plus apatinib outperformed the single therapy of S-1 therapy in mitigating the levels of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), and interleukin-10 (IL-10) ( P  < 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups ( P  > 0.05). S-1 therapy plus apatinib was associated with a significantly shorter TTP (5.2 ± 0.7 months) and a longer OS (9.3 ± 2.5 months) versus S-1 therapy alone (7.1 ± 1.3, 5.1 ± 1.3 months) ( P  < 0.05). Conclusion. The efficacy of apatinib plus S-1 therapy showed better improvement in lowering the serum tumor marker levels and ameliorating the Th1 and Th2-like cytokine levels versus S-1 therapy alone, so it is worthy of clinical application.

No abstract

No abstract